Our study's motive was to recognize various immune-mediated inflammatory processes involved in the pathogenesis of depression and psoriasis and interlink between them based on inflammatory mediators.
A careful and comprehensive literature search was done through various databases like PubMed, Google Scholar, and EBSCO. A total of 56 studies were included in our study after careful screening.
The immune-mediated inflammatory process was significantly associated with the pathogenesis of both depression and psoriasis. Most of the inflammatory markers involved in Psoriasis (TNF-α, IL-2, IL-6, IL-23, IL-1β, IL-10), and increased serotonin transporters (5-HTT) were also found in the pathogenesis of depression, showing the immune-inflammatory linkage between psoriasis and major depression. Based on immune chemistry, the levels of CD2+, CD4+, CD8+ T-lymphocytes were also found to be raised in both depression and psoriasis, validating their relationship. Hyperactivity of HPA-axis was also found another interlink between them along with reduced melatonin amount.
According to various studies, the neuro-dermatological association between psoriasis and depression is significant. Different immune markers involved in the pathogenesis of depression and psoriasis also show the bidirectional association between them. However, this association between psoriasis and depression is positively correlated, but more work is required to answer why all depressed patients fail to develop psoriasis and why all psoriatic patients fail to develop depression.
Citation: Shahzaib Maqbool, Arham Ihtesham, Muhammad Nadeem Langove, Sara Jamal, Tabdar Jamal, Hafiz Abu Safian. Neuro-dermatological association between psoriasis and depression: an immune-mediated inflammatory process validating skin-brain axis theory[J]. AIMS Neuroscience, 2021, 8(3): 340-354. doi: 10.3934/Neuroscience.2021018
[1] | Saima Rashid, Abdulaziz Garba Ahmad, Fahd Jarad, Ateq Alsaadi . Nonlinear fractional differential equations and their existence via fixed point theory concerning to Hilfer generalized proportional fractional derivative. AIMS Mathematics, 2023, 8(1): 382-403. doi: 10.3934/math.2023018 |
[2] | Muhammad Tariq, Sotiris K. Ntouyas, Hijaz Ahmad, Asif Ali Shaikh, Bandar Almohsen, Evren Hincal . A comprehensive review of Grüss-type fractional integral inequality. AIMS Mathematics, 2024, 9(1): 2244-2281. doi: 10.3934/math.2024112 |
[3] | Ahmed Alsaedi, Bashir Ahmad, Afrah Assolami, Sotiris K. Ntouyas . On a nonlinear coupled system of differential equations involving Hilfer fractional derivative and Riemann-Liouville mixed operators with nonlocal integro-multi-point boundary conditions. AIMS Mathematics, 2022, 7(7): 12718-12741. doi: 10.3934/math.2022704 |
[4] | Pinghua Yang, Caixia Yang . The new general solution for a class of fractional-order impulsive differential equations involving the Riemann-Liouville type Hadamard fractional derivative. AIMS Mathematics, 2023, 8(5): 11837-11850. doi: 10.3934/math.2023599 |
[5] | Ugyen Samdrup Tshering, Ekkarath Thailert, Sotiris K. Ntouyas . Existence and stability results for a coupled system of Hilfer-Hadamard sequential fractional differential equations with multi-point fractional integral boundary conditions. AIMS Mathematics, 2024, 9(9): 25849-25878. doi: 10.3934/math.20241263 |
[6] | Donny Passary, Sotiris K. Ntouyas, Jessada Tariboon . Hilfer fractional quantum system with Riemann-Liouville fractional derivatives and integrals in boundary conditions. AIMS Mathematics, 2024, 9(1): 218-239. doi: 10.3934/math.2024013 |
[7] | Ravi Agarwal, Snezhana Hristova, Donal O'Regan . Integral presentations of the solution of a boundary value problem for impulsive fractional integro-differential equations with Riemann-Liouville derivatives. AIMS Mathematics, 2022, 7(2): 2973-2988. doi: 10.3934/math.2022164 |
[8] | Bashir Ahmad, Manal Alnahdi, Sotiris K. Ntouyas, Ahmed Alsaedi . On a mixed nonlinear boundary value problem with the right Caputo fractional derivative and multipoint closed boundary conditions. AIMS Mathematics, 2023, 8(5): 11709-11726. doi: 10.3934/math.2023593 |
[9] | Asghar Ahmadkhanlu, Hojjat Afshari, Jehad Alzabut . A new fixed point approach for solutions of a p-Laplacian fractional q-difference boundary value problem with an integral boundary condition. AIMS Mathematics, 2024, 9(9): 23770-23785. doi: 10.3934/math.20241155 |
[10] | Muath Awadalla, Manigandan Murugesan, Subramanian Muthaiah, Bundit Unyong, Ria H Egami . Existence results for a system of sequential differential equations with varying fractional orders via Hilfer-Hadamard sense. AIMS Mathematics, 2024, 9(4): 9926-9950. doi: 10.3934/math.2024486 |
Our study's motive was to recognize various immune-mediated inflammatory processes involved in the pathogenesis of depression and psoriasis and interlink between them based on inflammatory mediators.
A careful and comprehensive literature search was done through various databases like PubMed, Google Scholar, and EBSCO. A total of 56 studies were included in our study after careful screening.
The immune-mediated inflammatory process was significantly associated with the pathogenesis of both depression and psoriasis. Most of the inflammatory markers involved in Psoriasis (TNF-α, IL-2, IL-6, IL-23, IL-1β, IL-10), and increased serotonin transporters (5-HTT) were also found in the pathogenesis of depression, showing the immune-inflammatory linkage between psoriasis and major depression. Based on immune chemistry, the levels of CD2+, CD4+, CD8+ T-lymphocytes were also found to be raised in both depression and psoriasis, validating their relationship. Hyperactivity of HPA-axis was also found another interlink between them along with reduced melatonin amount.
According to various studies, the neuro-dermatological association between psoriasis and depression is significant. Different immune markers involved in the pathogenesis of depression and psoriasis also show the bidirectional association between them. However, this association between psoriasis and depression is positively correlated, but more work is required to answer why all depressed patients fail to develop psoriasis and why all psoriatic patients fail to develop depression.
Segre [1] made a pioneering attempt in the development of special algebra. He conceptualized the commutative generalization of complex numbers, bicomplex numbers, tricomplex numbers, etc. as elements of an infinite set of algebras. Subsequently, in the 1930s, researchers contributed in this area [2,3,4]. The next fifty years failed to witness any advancement in this field. Later, Price [5] developed the bicomplex algebra and function theory. Recent works in this subject [6,7] find some significant applications in different fields of mathematical sciences as well as other branches of science and technology. An impressive body of work has been developed by a number of researchers. Among these works, an important work on elementary functions of bicomplex numbers has been done by Luna-Elizaarrarˊas et al. [8]. Choi et al. [9] proved some common fixed point theorems in connection with two weakly compatible mappings in bicomplex valued metric spaces. Jebril [10] proved some common fixed point theorems under rational contractions for a pair of mappings in bicomplex valued metric spaces. In 2017, Dhivya and Marudai [11] introduced the concept of a complex partial metric space, suggested a plan to expand the results and proved some common fixed point theorems under a rational expression contraction condition. In 2019, Mani and Mishra [12] proved coupled fixed point theorems on a complex partial metric space using different types of contractive conditions. In 2021, Gunaseelan et al. [13] proved common fixed point theorems on a complex partial metric space. In 2021, Beg et al.[14] proved fixed point theorems on a bicomplex valued metric space. In 2021, Zhaohui et al. [15] proved common fixed theorems on a bicomplex partial metric space. In this paper, we prove coupled fixed point theorems on a bicomplex partial metric space. An example is provided to verify the effectiveness and applicability of our main results. An application of these results to Fredholm integral equations and nonlinear integral equations is given.
Throughout this paper, we denote the set of real, complex and bicomplex numbers, respectively, as C0, C1 and C2. Segre [1] defined the complex number as follows:
z=ϑ1+ϑ2i1, |
where ϑ1,ϑ2∈C0, i21=−1. We denote the set ofcomplex numbers C1 as:
C1={z:z=ϑ1+ϑ2i1,ϑ1,ϑ2∈C0}. |
Let z∈C1; then, |z|=(ϑ21+ϑ22)12. The norm ||.|| of an element in C1 is the positive real valued function ||.||:C1→C+0 defined by
||z||=(ϑ21+ϑ22)12. |
Segre [1] defined the bicomplex number as follows:
ς=ϑ1+ϑ2i1+ϑ3i2+ϑ4i1i2, |
where ϑ1,ϑ2,ϑ3,ϑ4∈C0, and independent units i1,i2 are such that i21=i22=−1 and i1i2=i2i1. We denote the set of bicomplex numbers C2 as:
C2={ς:ς=ϑ1+ϑ2i1+ϑ3i2+ϑ4i1i2,ϑ1,ϑ2,ϑ3,ϑ4∈C0}, |
i.e.,
C2={ς:ς=z1+i2z2,z1,z2∈C1}, |
where z1=ϑ1+ϑ2i1∈C1 and z2=ϑ3+ϑ4i1∈C1. If ς=z1+i2z2 and η=ω1+i2ω2 are any two bicomplex numbers, then the sum is ς±η=(z1+i2z2)±(ω1+i2ω2)=z1±ω1+i2(z2±ω2), and the product is ς.η=(z1+i2z2)(ω1+i2ω2)=(z1ω1−z2ω2)+i2(z1ω2+z2ω1).
There are four idempotent elements in C2: They are 0,1,e1=1+i1i22,e2=1−i1i22 of which e1 and e2 are nontrivial, such that e1+e2=1 and e1e2=0. Every bicomplex number z1+i2z2 can be uniquely expressed as the combination of e1 and e2, namely
ς=z1+i2z2=(z1−i1z2)e1+(z1+i1z2)e2. |
This representation of ς is known as the idempotent representation of a bicomplex number, and the complex coefficients ς1=(z1−i1z2) and ς2=(z1+i1z2) are known as the idempotent components of the bicomplex number ς.
An element ς=z1+i2z2∈C2 is said to be invertible if there exists another element η in C2 such that ςη=1, and η is said to be inverse (multiplicative) of ς. Consequently, ς is said to be the inverse(multiplicative) of η. An element which has an inverse in C2 is said to be a non-singular element of C2, and an element which does not have an inverse in C2 is said to be a singular element of C2.
An element ς=z1+i2z2∈C2 is non-singular if and only if ||z21+z22||≠0 and singular if and only if ||z21+z22||=0. When it exists, the inverse of ς is as follows.
ς−1=η=z1−i2z2z21+z22. |
Zero is the only element in C0 which does not have a multiplicative inverse, and in C1, 0=0+i10 is the only element which does not have a multiplicative inverse. We denote the set of singular elements of C0 and C1 by O0 and O1, respectively. However, there is more than one element in C2 which does not have a multiplicative inverse: for example, e1 and e2. We denote this set by O2, and clearly O0={0}=O1⊂O2.
A bicomplex number ς=ϑ1+ϑ2i1+ϑ3i2+ϑ4i1i2∈C2 is said to be degenerated (or singular) if the matrix
(ϑ1ϑ2ϑ3ϑ4) |
is degenerated (or singular). The norm ||.|| of an element in C2 is the positive real valued function ||.||:C2→C+0 defined by
||ς||=||z1+i2z2||={||z21||+||z22||}12=[|z1−i1z2|2+|z1+i1z2|22]12=(ϑ21+ϑ22+ϑ23+ϑ24)12, |
where ς=ϑ1+ϑ2i1+ϑ3i2+ϑ4i1i2=z1+i2z2∈C2.
The linear space C2 with respect to a defined norm is a normed linear space, and C2 is complete. Therefore, C2 is a Banach space. If ς,η∈C2, then ||ςη||≤√2||ς||||η|| holds instead of ||ςη||≤||ς||||η||, and therefore C2 is not a Banach algebra. For any two bicomplex numbers ς,η∈C2, we can verify the following:
1. ς⪯i2η⟺||ς||≤||η||,
2. ||ς+η||≤||ς||+||η||,
3. ||ϑς||=|ϑ|||ς||, where ϑ is a real number,
4. ||ςη||≤√2||ς||||η||, and the equality holds only when at least one of ς and η is degenerated,
5. ||ς−1||=||ς||−1 if ς is a degenerated bicomplex number with 0≺ς,
6. ||ςη||=||ς||||η||, if η is a degenerated bicomplex number.
The partial order relation ⪯i2 on C2 is defined as follows. Let C2 be the set of bicomplex numbers and ς=z1+i2z2, η=ω1+i2ω2∈C2. Then, ς⪯i2η if and only if z1⪯ω1 and z2⪯ω2, i.e., ς⪯i2η if one of the following conditions is satisfied:
1. z1=ω1, z2=ω2,
2. z1≺ω1, z2=ω2,
3. z1=ω1, z2≺ω2,
4. z1≺ω1, z2≺ω2.
In particular, we can write ς⋦i2η if ς⪯i2η and ς≠η, i.e., one of 2, 3 and 4 is satisfied, and we will write ς≺i2η if only 4 is satisfied.
Now, let us recall some basic concepts and notations, which will be used in the sequel.
Definition 2.1. [15] A bicomplex partial metric on a non-void set U is a function ρbcpms:U×U→C+2, where C+2={ς:ς=ϑ1+ϑ2i1+ϑ3i2+ϑ4i1i2,ϑ1,ϑ2,ϑ3,ϑ4∈C+0} and C+0={ϑ1∈C0|ϑ1≥0} such that for all φ,ζ,z∈U:
1. 0⪯i2ρbcpms(φ,φ)⪯i2ρbcpms(φ,ζ) (small self-distances),
2. ρbcpms(φ,ζ)=ρbcpms(ζ,φ) (symmetry),
3. ρbcpms(φ,φ)=ρbcpms(φ,ζ)=ρbcpms(ζ,ζ) if and only if φ=ζ (equality),
4. ρbcpms(φ,ζ)⪯i2ρbcpms(φ,z)+ρbcpms(z,ζ)−ρbcpms(z,z) (triangularity) .
A bicomplex partial metric space is a pair (U,ρbcpms) such that U is a non-void set and ρbcpms is a bicomplex partial metric on U.
Example 2.2. Let U=[0,∞) be endowed with bicomplex partial metric space ρbcpms:U×U→C+2 with ρbcpms(φ,ζ)=max{φ,ζ}ei2θ, where ei2θ=cosθ+i2sinθ, for all φ,ζ∈U and 0≤θ≤π2. Obviously, (U,ρbcpms) is a bicomplex partial metric space.
Definition 2.3. [15] A bicomplex partial metric space U is said to be a T0 space if for any pair of distinct points of U, there exists at least one open set which contains one of them but not the other.
Theorem 2.4. [15] Let (U,ρbcpms) be a bicomplex partial metric space; then, (U,ρbcpms) is T0.
Definition 2.5. [15] Let (U,ρbcpms) be a bicomplex partial metric space. A sequence {φτ} in U is said to be convergent and converges to φ∈U if for every 0≺i2ϵ∈C+2 there exists N∈N such that φτ∈Bρbcpms(φ,ϵ)={ω∈U:ρbcpms(φ,ω)<ϵ+ρbcpms(φ,φ)} for all τ≥N, and it is denoted by limτ→∞φτ=φ.
Lemma 2.6. [15] Let (U,ρbcpms) be a bicomplex partial metric space. A sequence {φτ}∈U is converges to φ∈U iff ρbcpms(φ,φ)=limτ→∞ρbcpms(φ,φτ).
Definition 2.7. [15] Let (U,ρbcpms) be a bicomplex partial metric space. A sequence {φτ} in U is said to be a Cauchy sequence in (U,ρbcpms) if for any ϵ>0 there exist ϑ∈C+2 and N∈N such that ||ρbcpms(φτ,φυ)−ϑ||<ϵ for all τ,υ≥N.
Definition 2.8. [15] Let (U,ρbcpms) be a bicomplex partial metric space. Let {φτ} be any sequence in U. Then,
1. If every Cauchy sequence in U is convergent in U, then (U,ρbcpms) is said to be a complete bicomplex partial metric space.
2. A mapping S:U→U is said to be continuous at φ0∈U if for every ϵ>0, there exists δ>0 such that S(Bρbcpms(φ0,δ))⊂Bρbcpms(S(φ0,ϵ)).
Lemma 2.9. [15] Let (U,ρbcpms) be a bicomplex partial metric space and {φτ} be a sequence in U. Then, {φτ} is a Cauchy sequence in U iff limτ,υ→∞ρbcpms(φτ,φυ)=ρbcpms(φ,φ).
Definition 2.10. Let (U,ρbcpms) be a bicomplex partial metric space. Then, an element (φ,ζ)∈U×U is said to be a coupled fixed point of the mapping S:U×U→U if S(φ,ζ)=φ and S(ζ,φ)=ζ.
Theorem 2.11. [15] Let (U,ρbcpms) be a complete bicomplex partial metric space and S,T:U→U be two continuous mappings such that
ρbcpms(Sφ,Tζ)⪯i2lmax{ρbcpms(φ,ζ),ρbcpms(φ,Sφ),ρbcpms(ζ,Tζ),12(ρbcpms(φ,Tζ)+ρbcpms(ζ,Sφ))}, |
for all φ,ζ∈U, where 0≤l<1. Then, the pair (S,T) has a unique common fixed point, and ρbcpms(φ∗,φ∗)=0.
Inspired by Theorem 2.11, here we prove coupled fixed point theorems on a bicomplex partial metric space with an application.
Theorem 3.1. Let (U,ρbcpms) be a complete bicomplex partial metric space. Suppose that the mapping S:U×U→U satisfies the following contractive condition:
ρbcpms(S(φ,ζ),S(ν,μ))⪯i2λρbcpms(S(φ,ζ),φ)+lρbcpms(S(ν,μ),ν), |
for all φ,ζ,ν,μ∈U, where λ,l are nonnegative constants with λ+l<1. Then, S has a unique coupled fixed point.
Proof. Choose ν0,μ0∈U and set ν1=S(ν0,μ0) and μ1=S(μ0,ν0). Continuing this process, set ντ+1=S(ντ,μτ) and μτ+1=S(μτ,ντ). Then,
ρbcpms(ντ,ντ+1)=ρbcpms(S(ντ−1,μτ−1),S(ντ,μτ))⪯i2λρbcpms(S(ντ−1,μτ−1),ντ−1)+lρbcpms(S(ντ,μτ),ντ)=λρbcpms(ντ,ντ−1)+lρbcpms(ντ+1,ντ)ρbcpms(ντ,ντ+1)⪯i2λ1−lρbcpms(ντ,ντ−1), |
which implies that
||ρbcpms(ντ,ντ+1)||≤z||ρbcpms(ντ−1,ντ)|| | (3.1) |
where z=λ1−l<1. Similarly, one can prove that
||ρbcpms(μτ,μτ+1)||≤z||ρbcpms(μτ−1,μτ)||. | (3.2) |
From (3.1) and (3.2), we get
||ρbcpms(ντ,ντ+1)||+||ρbcpms(μτ,μτ+1)||≤z(||ρbcpms(ντ−1,ντ)||+||ρbcpms(μτ−1,μτ)||), |
where z<1.
Also,
||ρbcpms(ντ+1,ντ+2)||≤z||ρbcpms(ντ,ντ+1)|| | (3.3) |
||ρbcpms(μτ+1,μτ+2)||≤z||ρbcpms(μτ,μτ+1)||. | (3.4) |
From (3.3) and (3.4), we get
||ρbcpms(ντ+1,ντ+2)||+||ρbcpms(μτ+1,μτ+2)||≤z(||ρbcpms(ντ,ντ+1)||+||ρbcpms(μτ,μτ+1)||). |
Repeating this way, we get
||ρbcpms(ντ,ντ+1)||+||ρbcpms(μτ,μτ+1)||≤z(||ρbcpms(μτ−1,μτ)||+||ρbcpms(ντ−1,ντ)||)≤z2(||ρbcpms(μτ−2,μτ−1)||+||ρbcpms(ντ−2,ντ−1)||)≤⋯≤zτ(||ρbcpms(μ0,μ1)||+||ρbcpms(ν0,ν1)||). |
Now, if ||ρbcpms(ντ,ντ+1)||+||ρbcpms(μτ,μτ+1)||=γτ, then
γτ≤zγτ−1≤⋯≤zτγ0. | (3.5) |
If γ0=0, then ||ρbcpms(ν0,ν1)||+||ρbcpms(μ0,μ1)||=0. Hence, ν0=ν1=S(ν0,μ0) and μ0=μ1=S(μ0,μ0), which implies that (ν0,μ0) is a coupled fixed point of S. Let γ0>0. For each τ≥υ, we have
ρbcpms(ντ,νυ)⪯i2ρbcpms(ντ,ντ−1)+ρbcpms(ντ−1,ντ−2)−ρbcpms(ντ−1,ντ−1)+ρbcpms(ντ−2,ντ−3)+ρbcpms(ντ−3,ντ−4)−ρbcpms(ντ−3,ντ−3)+⋯+ρbcpms(νυ+2,νυ+1)+ρbcpms(νυ+1,νυ)−ρbcpms(νυ+1,νυ+1)⪯i2ρbcpms(ντ,ντ−1)+ρbcpms(ντ−1,ντ−2)+⋯+ρbcpms(νυ+1,νυ), |
which implies that
||ρbcpms(ντ,νυ)||≤||ρbcpms(ντ,ντ−1)||+||ρbcpms(ντ−1,ντ−2)||+⋯+||ρbcpms(νυ+1,νυ)||. |
Similarly, one can prove that
||ρbcpms(μτ,μυ)||≤||ρbcpms(μτ,μτ−1)||+||ρbcpms(μτ−1,μτ−2)||+⋯+||ρbcpms(μυ+1,μυ)||. |
Thus,
||ρbcpms(ντ,νυ)||+||ρbcpms(μτ,μυ)||≤γτ−1+γτ−2+γτ−3+⋯+γυ≤(zτ−1+zτ−2+⋯+zυ)γ0≤zυ1−zγ0→0asυ→∞, |
which implies that {ντ} and {μτ} are Cauchy sequences in (U,ρbcpms). Since the bicomplex partial metric space (U,ρbcpms) is complete, there exist ν,μ∈U such that {ντ}→ν and {μτ}→μ as τ→∞, and
ρbcpms(ν,ν)=limτ→∞ρbcpms(ν,ντ)=limτ,υ→∞ρbcpms(ντ,νυ)=0,ρbcpms(μ,μ)=limτ→∞ρbcpms(μ,μτ)=limτ,υ→∞ρbcpms(μτ,μυ)=0. |
We now show that ν=S(ν,μ). We suppose on the contrary that ν≠S(ν,μ) and μ≠S(μ,ν), so that 0≺i2ρbcpms(ν,S(ν,μ))=l1 and 0≺i2ρbcpms(μ,S(μ,ν))=l2. Then,
l1=ρbcpms(ν,S(ν,μ))⪯i2ρbcpms(ν,ντ+1)+ρbcpms(ντ+1,S(ν,μ))=ρbcpms(ν,ντ+1)+ρbcpms(S(ντ,μτ),S(ν,μ))⪯i2ρbcpms(ν,ντ+1)+λρbcpms(ντ−1,ντ)+lρbcpms(S(ν,μ),ν)⪯i211−lρbcpms(ν,ντ+1)+λ1−lρbcpms(ντ−1,ντ), |
which implies that
||l1||≤11−l||ρbcpms(ν,ντ+1)||+λ1−l||ρbcpms(ντ−1,ντ)||. |
As τ→∞, ||l1||≤0. This is a contradiction, and therefore ||ρbcpms(ν,S(ν,μ))||=0 implies ν=S(ν,μ). Similarly, we can prove that μ=S(μ,ν). Thus (ν,μ) is a coupled fixed point of S. Now, if (g,h) is another coupled fixed point of S, then
ρbcpms(ν,g)=ρbcpms(S(ν,μ),S(g,h))⪯i2λρbcpms(S(ν,μ),ν)+lρbcpms(S(g,h),g)=λρbcpms(ν,ν)+lρbcpms(g,g)=0. |
Thus, we have g=ν. Similarly, we get h=μ. Therefore S has a unique coupled fixed point.
Corollary 3.2. Let (U,ρbcpms) be a complete bicomplex partial metric space. Suppose that the mapping S:U×U→U satisfies the following contractive condition:
ρbcpms(S(φ,ζ),S(ν,μ))⪯i2λ(ρbcpms(S(φ,ζ),φ)+ρbcpms(S(ν,μ),ν)), | (3.6) |
for all φ,ζ,ν,μ∈U, where 0≤λ<12. Then, S has a unique coupled fixed point.
Theorem 3.3. Let (U,ρbcpms) be a complete complex partial metric space. Suppose that the mapping S:U×U→U satisfies the following contractive condition:
ρbcpms(S(φ,ζ),S(ν,μ))⪯i2λρbcpms(φ,ν)+lρbcpms(ζ,μ), |
for all φ,ζ,ν,μ∈U, where λ,l are nonnegative constants with λ+l<1. Then, S has a unique coupled fixed point.
Proof. Choose ν0,μ0∈U and set ν1=S(ν0,μ0) and μ1=S(μ0,ν0). Continuing this process, set ντ+1=S(ντ,μτ) and μτ+1=S(μτ,ντ). Then,
ρbcpms(ντ,ντ+1)=ρbcpms(S(ντ−1,μτ−1),S(ντ,μτ))⪯i2λρbcpms(ντ−1,ντ)+lρbcpms(μτ−1,μτ), |
which implies that
||ρbcpms(ντ,ντ+1)||≤λ||ρbcpms(ντ−1,ντ)||+l||ρbcpms(μτ−1,μτ)||. | (3.7) |
Similarly, one can prove that
||ρbcpms(μτ,μτ+1)||≤λ||ρbcpms(μτ−1,μτ)||+l||ρbcpms(ντ−1,ντ)||. | (3.8) |
From (3.7) and (3.8), we get
||ρbcpms(ντ,ντ+1)||+||ρbcpms(μτ,μτ+1)||≤(λ+l)(||ρbcpms(μτ−1,μτ)||+||ρbcpms(ντ−1,ντ)||)=α(||ρbcpms(μτ−1,μτ)||+||ρbcpms(ντ−1,ντ)||), |
where α=λ+l<1. Also,
||ρbcpms(ντ+1,ντ+2)||≤λ||ρbcpms(ντ,ντ+1)||+l||ρbcpms(μτ,μτ+1)|| | (3.9) |
||ρbcpms(μτ+1,μτ+2)||≤λ||ρbcpms(μτ,μτ+1)||+l||ρbcpms(ντ,ντ+1)||. | (3.10) |
From (3.9) and (3.10), we get
||ρbcpms(ντ+1,ντ+2)||+||ρbcpms(μτ+1,μτ+2)||≤(λ+l)(||ρbcpms(μτ,μτ+1)||+||ρbcpms(ντ,ντ+1)||)=α(||ρbcpms(μτ,μτ+1)||+||ρbcpms(ντ,ντ+1)||). |
Repeating this way, we get
||ρbcpms(ντ,νn+1)||+||ρbcpms(μτ,μτ+1)||≤α(||ρbcpms(μτ−1,μτ)||+||ρbcpms(ντ−1,ντ)||)≤α2(||ρbcpms(μτ−2,μτ−1)||+||ρbcpms(ντ−2,ντ−1)||)≤⋯≤ατ(||ρbcpms(μ0,μ1)||+||ρbcpms(ν0,ν1)||). |
Now, if ||ρbcpms(ντ,ντ+1)||+||ρbcpms(μτ,μτ+1)||=γτ, then
γτ≤αγτ−1≤⋯≤ατγ0. | (3.11) |
If γ0=0, then ||ρbcpms(ν0,ν1)||+||ρbcpms(μ0,μ1)||=0. Hence, ν0=ν1=S(ν0,μ0) and μ0=μ1=S(μ0,ν0), which implies that (ν0,μ0) is a coupled fixed point of S. Let γ0>0. For each τ≥υ, we have
ρbcpms(ντ,νυ)⪯i2ρbcpms(ντ,ντ−1)+ρbcpms(ντ−1,ντ−2)−ρbcpms(ντ−1,ντ−1)+ρbcpms(ντ−2,ντ−3)+ρbcpms(ντ−3,ντ−4)−ρbcpms(ντ−3,ντ−3)+⋯+ρbcpms(νυ+2,νυ+1)+ρbcpms(νυ+1,νυ)−ρbcpms(νυ+1,νυ+1)⪯i2ρbcpms(ντ,ντ−1)+ρbcpms(ντ−1,ντ−2)+⋯+ρbcpms(νυ+1,νυ), |
which implies that
||ρbcpms(ντ,νυ)||≤||ρbcpms(ντ,ντ−1)||+||ρbcpms(ντ−1,ντ−2)||+⋯+||ρbcpms(νυ+1,νυ)||. |
Similarly, one can prove that
||ρbcpms(μτ,μυ)||≤||ρbcpms(μτ,μτ−1)||+||ρbcpms(μτ−1,μτ−2)||+⋯+||ρbcpms(μυ+1,μυ)||. |
Thus,
||ρbcpms(ντ,νυ)||+||ρbcpms(μτ,μυ)||≤γτ−1+γτ−2+γτ−3+⋯+γυ≤(ατ−1+ατ−2+⋯+αυ)γ0≤αυ1−αγ0asτ→∞, |
which implies that {ντ} and {μτ} are Cauchy sequences in (U,ρbcpms). Since the bicomplex partial metric space (U,ρbcpms) is complete, there exist ν,μ∈U such that {ντ}→ν and {μτ}→μ as τ→∞, and
ρbcpms(ν,ν)=limτ→∞ρbcpms(ν,ντ)=limτ,υ→∞ρbcpms(ντ,νυ)=0,ρbcpms(μ,μ)=limτ→∞ρbcpms(μ,μτ)=limτ,υ→∞ρbcpms(μτ,μυ)=0. |
Therefore,
ρbcpms(S(ν,μ),ν)≤ρbcpms(S(ν,μ),ντ+1)+ρbcpms(ντ+1,ν)−ρbcpms(ντ+1,ντ+1),≤ρbcpms(S(ν,μ)),S(ντ,μτ)+ρbcpms(ντ+1,ν)≤λρbcpms(ντ,ν)+lρbcpms(μτ,μ)+ρbcpms(ντ+1,ν). |
As τ→∞, from (3.6) and (3.12) we obtain ρbcpms(S(ν,μ),ν)=0. Therefore S(ν,μ)=ν. Similarly, we can prove S(μ,ν)=μ, which implies that (ν,μ) is a coupled fixed point of S. Now, if (g1,h1) is another coupled fixed point of S, then
ρbcpms(g1,ν)=ρbcpms(S(g1,h1),S(ν,μ))⪯i2λρbcpms(g1,ν)+lρbcpms(h1,μ),ρbcpms(h1,μ)=ρbcpms(S(h1,g1),S(μ,ν))⪯i2λρbcpms(h1,μ)+lρbcpms(g1,ν), |
which implies that
||ρbcpms(g1,ν)||≤λ||ρbcpms(g1,ν)||+l||ρbcpms(h1,μ)||, | (3.12) |
||ρbcpms(h1,μ)||≤λ||ρbcpms(h1,μ)||+l||ρbcpms(g1,ν)||. | (3.13) |
From (3.12) and (3.13), we get
||ρbcpms(g1,ν)||+||ρbcpms(h1,μ)||≤(λ+l)[||ρbcpms(g1,ν)||+||ρbcpms(h1,μ)||]. |
Since λ+l<1, this implies that ||ρbcpms(g1,ν)||+||ρbcpms(h1,μ)||=0. Therefore, ν=g1 and μ=h1. Thus, S has a unique coupled fixed point.
Corollary 3.4. Let (U,ρbcpms) be a complete bicomplex partial metric space. Suppose that the mapping S:U×U→U satisfies the following contractive condition:
ρbcpms(S(φ,ζ),S(ν,μ))⪯i2λ(ρbcpms(φ,ν)+ρbcpms(ζ,μ)), | (3.14) |
for all φ,ζ,ν,μ∈U, where 0≤λ<12. Then, S has a unique coupled fixed point.
Example 3.5. Let U=[0,∞) and define the bicomplex partial metric ρbcpms:U×U→C+2 defined by
ρbcpms(φ,ζ)=max{φ,ζ}ei2θ,0≤θ≤π2. |
We define a partial order ⪯ in C+2 as φ⪯ζ iff φ≤ζ. Clearly, (U,ρbcpms) is a complete bicomplex partial metric space.
Consider the mapping S:U×U→U defined by
S(φ,ζ)=φ+ζ4∀φ,ζ∈U. |
Now,
ρbcpms(S(φ,ζ),S(ν,μ))=ρbcpms(φ+ζ4,ν+μ4)=14max{φ+ζ,ν+μ}ei2θ⪯i214[max{φ,ν}+max{ζ,μ}]ei2θ=14[ρbcpms(φ,ν)+ρbcpms(ζ,μ)]=λ(ρbcpms(φ,ν)+ρbcpms(ζ,μ)), |
for all φ,ζ,ν,μ∈U, where 0≤λ=14<12. Therefore, all the conditions of Corollary 3.4 are satisfied, then the mapping S has a unique coupled fixed point (0,0) in U.
As an application of Theorem 3.3, we find an existence and uniqueness result for a type of the following system of nonlinear integral equations:
φ(μ)=∫M0κ(μ,p)[G1(p,φ(p))+G2(p,ζ(p))]dp+δ(μ),ζ(μ)=∫M0κ(μ,p)[G1(p,ζ(p))+G2(p,φ(p))]dp+δ(μ),μ,∈[0,M],M≥1. | (4.1) |
Let U=C([0,M],R) be the class of all real valued continuous functions on [0,M]. We define a partial order ⪯ in C+2 as x⪯y iff x≤y. Define S:U×U→U by
S(φ,ζ)(μ)=∫M0κ(μ,p)[G1(p,φ(p))+G2(p,ζ(p))]dp+δ(μ). |
Obviously, (φ(μ),ζ(μ)) is a solution of system of nonlinear integral equations (4.1) iff (φ(μ),ζ(μ)) is a coupled fixed point of S. Define ρbcpms:U×U→C2 by
ρbcpms(φ,ζ)=(|φ−ζ|+1)ei2θ, |
for all φ,ζ∈U, where 0≤θ≤π2. Now, we state and prove our result as follows.
Theorem 4.1. Suppose the following:
1. The mappings G1:[0,M]×R→R, G2:[0,M]×R→R, δ:[0,M]→R and κ:[0,M]×R→[0,∞) are continuous.
2. There exists η>0, and λ,l are nonnegative constants with λ+l<1, such that
|G1(p,φ(p))−G1(p,ζ(p))|⪯i2ηλ(|φ−ζ|+1)−12,|G2(p,ζ(p))−G2(p,φ(p))|⪯i2ηl(|ζ−φ|+1)−12. |
3. ∫M0η|κ(μ,p)|dp⪯i21.
Then, the integral equation (4.1) has a unique solution in U.
Proof. Consider
ρbcpms(S(φ,ζ),S(ν,Φ))=(|S(φ,ζ)−S(ν,Φ)|+1)ei2θ=(|∫M0κ(μ,p)[G1(p,φ(p))+G2(p,ζ(p))]dp+δ(μ)−(∫M0κ(μ,p)[G1(p,ν(p))+G2(p,Φ(p))]dp+δ(μ))|+1)ei2θ=(|∫M0κ(μ,p)[G1(p,φ(p))−G1(p,ν(p))+G2(p,ζ(p))−G2(p,Φ(p))]dp|+1)ei2θ⪯i2(∫M0|κ(μ,p)|[|G1(p,φ(p))−G1(p,ν(p))|+|G2(p,ζ(p))−G2(p,Φ(p))|]dp+1)ei2θ⪯i2(∫M0|κ(μ,p)|dp(ηλ(|φ−ν|+1)−12+ηl(|ζ−Φ|+1)−12)+1)ei2θ=(∫M0η|κ(μ,p)|dp(λ(|φ−ν|+1)+l(|ζ−Φ|+1)))ei2θ⪯i2(λ(|φ−ν|+1)+l(|ζ−Φ|+1))ei2θ=λρbcpms(φ,ν)+lρbcpms(ζ,Φ) |
for all φ,ζ,ν,Φ∈U. Hence, all the hypotheses of Theorem 3.3 are verified, and consequently, the integral equation (4.1) has a unique solution.
Example 4.2. Let U=C([0,1],R). Now, consider the integral equation in U as
φ(μ)=∫10μp23(μ+5)[11+φ(p)+12+ζ(p)]dp+6μ25ζ(μ)=∫10μp23(μ+5)[11+ζ(p)+12+φ(p)]dp+6μ25. | (4.2) |
Then, clearly the above equation is in the form of the following equation:
φ(μ)=∫M0κ(μ,p)[G1(p,φ(p))+G2(p,ζ(p))]dp+δ(μ),ζ(μ)=∫M0κ(μ,p)[G1(p,ζ(p))+G2(p,φ(p))]dp+δ(μ),μ,∈[0,M], | (4.3) |
where δ(μ)=6μ25, κ(μ,p)=μp23(μ+5), G1(p,μ)=11+μ, G2(p,μ)=12+μ and M=1. That is, (4.2) is a special case of (4.1) in Theorem 4.1. Here, it is easy to verify that the functions δ(μ), κ(μ,p), G1(p,μ) and G2(p,μ) are continuous. Moreover, there exist η=10, λ=13 and l=14 with λ+l<1 such that
|G1(p,φ)−G1(p,ζ)|≤ηλ(|φ−ζ|+1)−12,|G2(p,ζ)−G2(p,φ)|≤ηl(|ζ−φ|+1)−12 |
and ∫M0η|κ(μ,p)|dp=∫10ημp23(μ+5)dp=μη23(μ+5)<1. Therefore, all the conditions of Theorem 3.3 are satisfied. Hence, system (4.2) has a unique solution (φ∗,ζ∗) in U×U.
As an application of Corollary 3.4, we find an existence and uniqueness result for a type of the following system of Fredholm integral equations:
φ(μ)=∫EG(μ,p,φ(p),ζ(p))dp+δ(μ),μ,p∈E,ζ(μ)=∫EG(μ,p,ζ(p),φ(p))dp+δ(μ),μ,p∈E, | (4.4) |
where E is a measurable, G:E×E×R×R→R, and δ∈L∞(E). Let U=L∞(E). We define a partial order ⪯ in C+2 as x⪯y iff x≤y. Define S:U×U→U by
S(φ,ζ)(μ)=∫EG(μ,p,φ(p),ζ(p))dp+δ(μ). |
Obviously, (φ(μ),ζ(μ)) is a solution of the system of Fredholm integral equations (4.4) iff (φ(μ),ζ(μ)) is a coupled fixed point of S. Define ρbcpms:U×U→C2 by
ρbcpms(φ,ζ)=(|φ−ζ|+1)ei2θ, |
for all φ,ζ∈U, where 0≤θ≤π2. Now, we state and prove our result as follows.
Theorem 4.3. Suppose the following:
1. There exists a continuous function κ:E×E→R such that
|G(μ,p,φ(p),ζ(p))−G(μ,p,ν(p),Φ(p))|⪯i2|κ(μ,p)|(|φ(p)−ν(p)|+|ζ(p)−Φ(p)|−2), |
for all φ,ζ,ν,Φ∈U, μ,p∈E.
2. ∫E|κ(μ,p)|dp⪯i214⪯i21.
Then, the integral equation (4.4) has a unique solution in U.
Proof. Consider
ρbcpms(S(φ,ζ),S(ν,Φ))=(|S(φ,ζ)−S(ν,Φ)|+1)ei2θ=(|∫EG(μ,p,φ(p),ζ(p))dp+δ(μ)−(∫EG(μ,p,ν(p),Φ(p))dp+δ(μ))|+1)ei2θ=(|∫E(G(μ,p,φ(p),ζ(p))−G(μ,p,ν(p),Φ(p)))dp|+1)ei2θ⪯i2(∫E|G(μ,p,φ(p),ζ(p))−G(μ,p,ν(p),Φ(p))|dp+1)ei2θ⪯i2(∫E|κ(μ,p)|(|φ(p)−ν(p)|+|ζ(p)−Φ(p)|−2)dp+1)ei2θ⪯i2(∫E|κ(μ,p)|dp(|φ(p)−ν(p)|+|ζ(p)−Φ(p)|−2)+1)ei2θ⪯i214(|φ(p)−ν(p)|+|ζ(p)−Φ(p)|−2+4)ei2θ⪯i214(ρbcpms(φ,ν)+ρbcpms(ζ,Φ))=λ(ρbcpms(φ,ν)+ρbcpms(ζ,Φ)), |
for all φ,ζ,ν,Φ∈U, where 0≤λ=14<12. Hence, all the hypotheses of Corollary 3.4 are verified, and consequently, the integral equation (4.4) has a unique solution.
In this paper, we proved coupled fixed point theorems on a bicomplex partial metric space. An illustrative example and an application on a bicomplex partial metric space were given.
The authors declare no conflict of interest.
[1] |
Strain JJ (2017) Globalization of psychosomatic medicine. Gen Hosp Psychiatry 48: 62-64. doi: 10.1016/j.genhosppsych.2017.07.003
![]() |
[2] |
Brown GE, Malakouti M, Sorenson E, et al. (2015) Psychodermatology. Adv Psychosom Med 34: 123-134. doi: 10.1159/000369090
![]() |
[3] |
Leon A, Levin EC, Koo JY (2013) Psychodermatology: an overview. Semi Cutan Med Surg 32: 64-67. doi: 10.12788/j.sder.0002
![]() |
[4] |
Karam RA, Zidan HE, Khater MH (2014) Polymorphisms in the TNF-α and IL-10 gene promoters and risk of psoriasis and correlation with disease severity. Cytokine 66: 101-105. doi: 10.1016/j.cyto.2014.01.008
![]() |
[5] |
Parisi R, Symmons DP, Griffiths CE, et al. (2013) Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 133: 377-385. doi: 10.1038/jid.2012.339
![]() |
[6] | Ovčina-Kurtović N (2016) Significance of cytokine as a predictor for psoriasis Doctoral thesis Tuzla: Medical School of the University of Tuzla. |
[7] | Chong HT, Kopecki Z, Cowin AJ (2013) Lifting the silver flakes: the pathogenesis and management of chronic plaque psoriasis. Biomed Res Int 2013: 168321. |
[8] |
Huerta C, Rivero E, Garcia Rodriguez LA (2007) Incidence and risk factors for psoriasis in the general population. Arch Dermatol 143: 1559-1565. doi: 10.1001/archderm.143.12.1559
![]() |
[9] |
Krishnadas R, Nicol A, Sassarini J, et al. (2016) Circulating tumour necrosis factor is highly correlated with brainstem serotonin transporter availability in humans. Brain Behav Immune 51: 29-38. doi: 10.1016/j.bbi.2015.08.005
![]() |
[10] |
Hardy GE, Cotterill JA (1982) A study of depression and obsessionality in dysmorphophobic and psoriatic patients. Br J Psychiatry 140: 19-22. doi: 10.1192/bjp.140.1.19
![]() |
[11] |
Gupta MA, Gupta AK, Schork NJ, et al. (1994) Depression modulates pruritus perception: a study of pruritus in psoriasis, atopic dermatitis, and chronic idiopathic urticaria. Psychosom Med 56: 36-40. doi: 10.1097/00006842-199401000-00005
![]() |
[12] |
Renzi C, Picardi A, Abeni D, et al. (2002) Association of dissatisfaction with care and psychiatric morbidity with poor treatment compliance. Arch Dermatol 138: 337-342. doi: 10.1001/archderm.138.3.337
![]() |
[13] |
Buske-Kirschbaum A, Ebrecht M, Kern S, et al. (2006) Endocrine stress responses in TH1-mediated chronic inflammatory skin disease (psoriasis vulgaris)—do they parallel stress-induced endocrine changes in TH2-mediated inflammatory dermatoses (atopic dermatitis). Psychoneuroendocrinology 31: 439-446. doi: 10.1016/j.psyneuen.2005.10.006
![]() |
[14] |
Gupta MA, Gupta AK, Kirkby S, et al. (1989) A psychocutaneous profile of psoriasis patients who are stress reactors. A study of 127 patients. Gen Hosp Psychiatry 11: 166-173. doi: 10.1016/0163-8343(89)90036-4
![]() |
[15] | Matiushenko VP, Kutasevych YF, Havryliuk OA, et al. (2020) Effectiveness of psychopharmacotherapy in psoriasis patients with associated anxiety and depression. Dermatol Ther 33: e14292. |
[16] |
Fortune DG, Richards HL, Kirby B, et al. (2002) A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol 146: 458-465. doi: 10.1046/j.1365-2133.2002.04622.x
![]() |
[17] |
Redighieri IP, Maia T, Nadal MA, et al. (2011) Erythrodermic psoriasis with regression after prophylaxis with isoniazid and antidepressant therapy: case report. An Bras Dermatol 86: S141-S143. doi: 10.1590/S0365-05962011000700037
![]() |
[18] |
Menter A, Augustin M, Signorovitch J, et al. (2010) The effect of adalimumab on reducing depression in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol 62: 812-818. doi: 10.1016/j.jaad.2009.07.022
![]() |
[19] |
Griffiths CE, Barker JN (2007) Pathogenesis and clinical features of psoriasis. Lancet 370: 263-271. doi: 10.1016/S0140-6736(07)61128-3
![]() |
[20] |
Gelfand JM, Gladman DD, Mease PJ, et al. (2005) Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 53: 573. doi: 10.1016/j.jaad.2005.03.046
![]() |
[21] |
Palfreeman AC, McNamee KE, McCann FE (2013) New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. Drug Des Devel Ther 7: 201-210. doi: 10.2147/DDDT.S32713
![]() |
[22] |
Lowes MA, Suárez-Fariñas M, Krueger JG (2014) Immunology of psoriasis. Annu Rev Immunol 32: 227-255. doi: 10.1146/annurev-immunol-032713-120225
![]() |
[23] |
Van der Fits L, Mourits S, Voerman JS, et al. (2009) Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 182: 5836-5845. doi: 10.4049/jimmunol.0802999
![]() |
[24] | Nograles KE, Zaba LC, Guttman-Yassky E (2008) Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 159: 1092-1102. |
[25] |
Zaba LC, Krueger JG, Lowes MA (2009) Resident and “inflammatory” dendritic cells in human skin. J Invest Dermatol 129: 302-308. doi: 10.1038/jid.2008.225
![]() |
[26] |
Chu CC, Di Meglio P, Nestle FO (2011) Harnessing dendritic cells in inflammatory skin diseases. Semin Immuno 23: 28-41. doi: 10.1016/j.smim.2011.01.006
![]() |
[27] |
Nestle FO, Conrad C, Tun-Kyi A, et al. (2005) Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 202: 135-143. doi: 10.1084/jem.20050500
![]() |
[28] |
Nestle FO, Kaplan DH, Barker J (2009) Psoriasis. N Engl J Med 361: 496-509. doi: 10.1056/NEJMra0804595
![]() |
[29] |
Uyemura K, Yamamura M, Fivenson DF, et al. (1993) The cytokine network in lesional and lesion-free psoriatic skin is characterized by a Thelper type 1 cell-mediated response. J Invest Dermatol 101: 701-705. doi: 10.1111/1523-1747.ep12371679
![]() |
[30] |
Brunoni AR, Lotufo PA, Sabbag C, et al. (2015) Decreased brain-derived neurotrophic factor plasma levels in psoriasis patients. Braz J Med Biol Res 48: 711-714. doi: 10.1590/1414-431x20154574
![]() |
[31] |
Mora C, Zonca V, Riva MA, et al. (2018) Blood biomarkers and treatment response in major depression. Expert Rev Mol Diagn 18: 513-529. doi: 10.1080/14737159.2018.1470927
![]() |
[32] |
Rosenblat JD, Cha DS, Mansur RB, et al. (2014) Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog Neuropsychopharmacol Biol Psychiatry 53: 23-34. doi: 10.1016/j.pnpbp.2014.01.013
![]() |
[33] |
McNally L, Bhagwagar Z, Hannestad J (2008) Inflammation, glutamate, and glia in depression: a literature review. CNS Spectr 13: 501-510. doi: 10.1017/S1092852900016734
![]() |
[34] |
Wong ML, Dong C, Maestre-Mesa J, et al. (2008) Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response. Mol Psychiatry 13: 800-812. doi: 10.1038/mp.2008.59
![]() |
[35] |
Miller AH, Maletic V, Raison CL (2009) Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65: 732-741. doi: 10.1016/j.biopsych.2008.11.029
![]() |
[36] |
Raison CL, Capuron L, Miller AH (2006) Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 27: 24-31. doi: 10.1016/j.it.2005.11.006
![]() |
[37] |
Dantzer R (2004) Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur J Pharmacol 500: 399-411. doi: 10.1016/j.ejphar.2004.07.040
![]() |
[38] |
Mössner R, Mikova O, Koutsilieri E (2007) Consensus paper of the WFSBP Task Force on Biological Markers: biological markers in depression. World J Biol Psychiatry 8: 141-174. doi: 10.1080/15622970701263303
![]() |
[39] |
Reichenberg A, Yirmiya R, Schuld A, et al. (2001) Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 58: 445-452. doi: 10.1001/archpsyc.58.5.445
![]() |
[40] |
Raison CL, Borisov AS, Majer M, et al. (2009) Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol Psychiatry 65: 296-303. doi: 10.1016/j.biopsych.2008.08.010
![]() |
[41] |
Wu CW, Chen YC, Yu L, et al. (2007) Treadmill exercise counteracts the suppressive effects of peripheral lipopolysaccharide on hippocampal neurogenesis and learning and memory. J Neurochem 103: 2471-2481. doi: 10.1111/j.1471-4159.2007.04987.x
![]() |
[42] |
Keller J, Gomez R, Williams G, et al. (2017) HPA axis in major depression: cortisol, clinical symptomatology and genetic variation predict cognition. Mol Psychiatry 22: 527-536. doi: 10.1038/mp.2016.120
![]() |
[43] |
Brunoni AR, Santos IS, Sabbag C, et al. (2014) Psoriasis severity and hypothalamic-pituitary-adrenal axis function: results from the CALIPSO study. Braz J Med Biol Res 47: 1102-1106. doi: 10.1590/1414-431X20143762
![]() |
[44] | Mozzanica N, Tadini G, Radaelli A, et al. (1988) Plasma melatonin levels in psoriasis. Acta Derm Venereol 68: 312-316. |
[45] |
Quera Salva MA, Hartley S, Barbot F, et al. (2011) Circadian rhythms, melatonin and depression. Curr Pharm Des 17: 1459-1470. doi: 10.2174/138161211796197188
![]() |
[46] |
Kartha LB, Chandrashekar L, Rajappa M, et al. (2014) Serum melatonin levels in psoriasis and associated depressive symptoms. Clin Chem Lab Med 52: e123-e125. doi: 10.1515/cclm-2013-0957
![]() |
[47] |
Esposito E, Cuzzocrea S (2010) Anti-inflammatory activity of melatonin in central nervous system. Curr Neuropharmacol 8: 228-242. doi: 10.2174/157015910792246155
![]() |
[48] |
Tohid H, Aleem D, Jackson C (2016) Major Depression and Psoriasis: A Psychodermatological Phenomenon. Skin Pharmacol Physiol 29: 220-230. doi: 10.1159/000448122
![]() |
[49] |
Demirhan O, Demirbek B, Tunç E, et al. (2012) Identification of chromosome abnormalities in screening of a family with manic depression and psoriasis: predisposition to aneuploidy. Asian J Psychiatr 5: 169-174. doi: 10.1016/j.ajp.2012.02.005
![]() |
[50] |
Martínez-Ortega JM, Nogueras P, Muñoz-Negro JE, et al. (2019) Quality of life, anxiety and depressive symptoms in patients with psoriasis: A case-control study. J Psychosom Res 124: 109780. doi: 10.1016/j.jpsychores.2019.109780
![]() |
[51] | Nicholas MN, Gooderham M (2017) Psoriasis, Depression, and Suicidality. Skin Therapy Lett 22: 1-4. |
[52] |
Aleem D, Tohid H (2018) Pro-inflammatory Cytokines, Biomarkers, Genetics and the Immune System: A Mechanistic Approach of Depression and Psoriasis. Rev Colomb Psiquiatr 47: 177-186. doi: 10.1016/j.rcp.2017.03.002
![]() |
[53] |
Kannan S, Heller MM, Lee ES, et al. (2013) The role of tumor necrosis factor-alpha and other cytokines in depression: what dermatologists should know. J Dermatolog Treat 24: 148-152. doi: 10.3109/09546634.2011.619159
![]() |
[54] |
Komiya E, Tominaga M, Kamata Y, et al. (2020) Molecular and Cellular Mechanisms of Itch in Psoriasis. Int J Mol Sci 21: 8406. doi: 10.3390/ijms21218406
![]() |
[55] |
Moon HS, Mizara A, McBride SR (2013) Psoriasis and psychodermatology. Dermatol Ther 3: 117-130. doi: 10.1007/s13555-013-0031-0
![]() |
[56] |
Motivala SJ, Sarfatti A, Olmos L, et al. (2005) Inflammatory markers and sleep disturbance in major depression. Psychosom Med 67: 187-194. doi: 10.1097/01.psy.0000149259.72488.09
![]() |
1. | Sunisa Theswan, Sotiris K. Ntouyas, Bashir Ahmad, Jessada Tariboon, Existence Results for Nonlinear Coupled Hilfer Fractional Differential Equations with Nonlocal Riemann–Liouville and Hadamard-Type Iterated Integral Boundary Conditions, 2022, 14, 2073-8994, 1948, 10.3390/sym14091948 |